Gedeon Richter
Allergan and Gedeon Richter’s Vraylar posts strong Phase 3 data in bipolar depression
December 19, 2017Manufacturing and Production, Research and Development Allergan, Gedeon Richter, Vraylar, bipolar, bipolar depression, pharma
Vraylar (cariprazine), a drug developed as part of a partnership between Allergan and Gedeon Richter, has demonstrated strong results at …
Gedeon Richter named and shamed
September 9, 2013Medical Communications, Sales and Marketing ABPI, Gedeon Richter, PMCPA
Gedeon Richter (UK) has been named and shamed in advertisements by the PMCPA, which rules on breaches of the ABPI …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
